Nexalin Technology (NASDAQ:NXL – Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.28) earnings per share (EPS) for the quarter, Zacks reports. Nexalin Technology had a negative return on equity of 187.59% and a negative net margin of 3,407.98%. The firm had revenue of $0.03 million for the quarter.
Nexalin Technology Stock Performance
Shares of NASDAQ:NXL opened at $2.15 on Friday. The business’s 50 day simple moving average is $2.85 and its two-hundred day simple moving average is $2.48. The firm has a market cap of $28.60 million, a P/E ratio of -3.36 and a beta of 4.33. Nexalin Technology has a 52-week low of $0.35 and a 52-week high of $4.49.
Wall Street Analysts Forecast Growth
Separately, Maxim Group reissued a “hold” rating on shares of Nexalin Technology in a research note on Thursday, December 5th.
Nexalin Technology Company Profile
Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.
Further Reading
- Five stocks we like better than Nexalin Technology
- Top Biotech Stocks: Exploring Innovation Opportunities
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 Stocks With High ROE and Market-Beating Growth Potential
- 3 Stocks to Consider Buying in October
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
